Moderna Share Price Today
(NASDAQ: MRNA)

Name: Moderna Share Price Today (NASDAQ: MRNA) - Moderna Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Moderna share price is $39.42 & ₹3,415.35 as on 1 Feb 2025, 2.30 'hrs' IST

$39.42

▲

-1.62

(-3.95%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Moderna share price in Dollar and Rupees. Guide to invest in Moderna stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Moderna, along with analyst recommendations, forecasts, and comprehensive financials.

Moderna share price movements

Today's Low: $39.37
Today's High: $41.41
$39.42
0.13%
Downside
Day's Volatility :4.93%
Upside
4.81%
52 Weeks Low: $31.94
52 Weeks High: $170.47
$39.42
18.98%
Downside
52 Weeks Volatility :81.26%
Upside
76.88%

Moderna (MRNA) Returns

Period	Moderna, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-26.37%	-0.6%	0.0%
6 Months	-52.93%	-2.8%	0.0%
1 Year	-59.57%	3.3%	0.0%
3 Years	-76.76%	11.6%	-13.7%

Moderna (MRNA) Key Statistics

in dollars & INR

Previous Close	$41.04
Open	$41.185
Today's High	$41.41
Today's Low	$39.37
Market Capitalization	$15.8B
Today's Volume	$6.5M
52 Week High	$170.47
52 Week Low	$31.94
Revenue TTM	$5.1B
EBITDA	$-2.4B
Earnings Per Share (EPS)	$-5.81
Profit Margin	-43.77%
Quarterly Earnings Growth YOY	-0.85%
Return On Equity TTM	-17.52%

How to invest in Moderna Stock (MRNA) from India?

It is very easy for Indian residents to invest directly in Moderna from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Moderna stock in both Indian Rupees (INR) and US Dollars (USD). Search for Moderna or MRNA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Moderna or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Moderna shares which would translate to 0.022 fractional shares of Moderna as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Moderna, in just a few clicks!

Returns in Moderna (MRNA) for Indian investors in Rupees

The Moderna stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Moderna investment value today

Current value as on today

₹44,990

Returns

₹55,010

(-55.01%)

Returns from Moderna Stock

₹59,569 (-59.57%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Moderna (MRNA)

103.85%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Investment in Moderna Shares from India has grown by 103.85% over the past 30 days, indicating increased transactional activity.

99%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Moderna Stock from India on INDmoney has increased by 99% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Moderna Stock (MRNA Ticker)

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	2921	-28.13	0.03%

Global Institutional Holdings in Moderna

Baillie Gifford & Co Limited.
11.03%
Vanguard Group Inc
10.45%
BlackRock Inc
6.50%
FMR Inc
4.52%
State Street Corp
4.38%
Theleme Partners LLP
1.88%

Analyst Recommendation on Moderna

Buy

54%Buy

35%Hold

9%Sell

Based on 31 Wall street analysts offering stock ratings for Moderna(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Moderna Stock (MRNA)

What analysts predicted

Upside of 59.72%

Target:

$62.96

Current:

$39.42

Insights on Moderna Stock (Ticker Symbol: MRNA)

Price Movement
In the last 6 months, MRNA stock has moved down by -58.1%
Increasing Revenue
Revenue is up for the last 3 quarters, 167.0M → 1.85B (in $), with an average increase of 58.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -1.27B → 13.0M (in $), with an average increase of 9938.5% per quarter
MRNA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 115.3%
MRNA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 164.4%
Price to Sales
ForMRNA every $1 of sales, investors are willing to pay $3.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

MRNA Moderna Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$122.5M	↓ 30.77%
Net Income	$-384.7M	↑ 50.34%
Net Profit Margin	-314.04%	↓ 169.43%

	FY19	Y/Y Change
Revenue	$48.0M	↓ 60.79%
Net Income	$-514.0M	↑ 33.6%
Net Profit Margin	-1.1K%	↓ 756.03%

	FY20	Y/Y Change
Revenue	$274.5M	↑ 471.43%
Net Income	$-747.1M	↑ 45.34%
Net Profit Margin	-272.16%	↑ 797.91%

	FY21	Y/Y Change
Revenue	$17.7B	↑ 6361.44%
Net Income	$12.2B	↓ 1733.33%
Net Profit Margin	68.8%	↑ 340.96%

	FY22	Y/Y Change
Revenue	$19.3B	↑ 8.61%
Net Income	$8.4B	↓ 31.47%
Net Profit Margin	43.41%	↓ 25.39%

	FY23	Y/Y Change
Revenue	$6.8B	↓ 64.45%
Net Income	$-4.7B	↓ 156.37%
Net Profit Margin	-68.84%	↓ 112.25%

	Q2 FY23	Q/Q Change
Revenue	$344.0M	↓ 81.53%
Net Income	$-1.4B	↓ 1846.84%
Net Profit Margin	-401.16%	↓ 405.4%

	Q3 FY23	Q/Q Change
Revenue	$1.8B	↑ 432.27%
Net Income	$-3.6B	↑ 163.04%
Net Profit Margin	-198.25%	↑ 202.91%

	Q4 FY23	Q/Q Change
Revenue	$2.8B	↑ 53.63%
Net Income	$217.0M	↓ 105.98%
Net Profit Margin	7.71%	↑ 205.96%

	Q1 FY24	Q/Q Change
Revenue	$167.0M	↓ 94.06%
Net Income	$-1.2B	↓ 641.47%
Net Profit Margin	-703.59%	↓ 711.3%

	Q2 FY24	Q/Q Change
Revenue	$241.0M	↑ 44.31%
Net Income	$-1.3B	↑ 8.85%
Net Profit Margin	-530.71%	↑ 172.88%

	Q3 FY24	Q/Q Change
Revenue	$1.9B	↑ 669.71%
Net Income	$13.0M	↓ 101.02%
Net Profit Margin	0.7%	↑ 531.41%

	FY18	Y/Y Change
Profit	$-331.6M	↓ 287.36%

	FY19	Y/Y Change
Profit	$48.0M	↓ 114.49%

	FY20	Y/Y Change
Profit	$266.6M	↑ 454.91%

	FY21	Y/Y Change
Profit	$15.1B	↑ 5571.96%

	FY22	Y/Y Change
Profit	$13.8B	↓ 8.41%

	FY23	Y/Y Change
Profit	$2.2B	↓ 84.44%

	Q2 FY23	Q/Q Change
Profit	$-387.0M	↓ 136.17%

	Q3 FY23	Q/Q Change
Profit	$-410.0M	↑ 5.94%

	Q4 FY23	Q/Q Change
Profit	$1.9B	↓ 559.51%

	Q1 FY24	Q/Q Change
Profit	$35.0M	↓ 98.14%

	Q2 FY24	Q/Q Change
Profit	$85.0M	↑ 142.86%

	Q3 FY24	Q/Q Change
Profit	$1.3B	↑ 1477.65%

	FY18	Y/Y Change
Operating Cash Flow	$-330.9M	↓ 0.19%
Investing Cash Flow	$-372.5M	↓ 189.24%
Financing Cash Flow	$1.2B	↑ 730163.1%

	FY19	Y/Y Change
Operating Cash Flow	$-459.0M	↑ 38.72%
Investing Cash Flow	$-14.9M	↓ 95.99%
Financing Cash Flow	$51.1M	↓ 95.83%

	FY20	Y/Y Change
Operating Cash Flow	$2.0B	↓ 541.64%
Investing Cash Flow	$-1.7B	↑ 11087.21%
Financing Cash Flow	$2.0B	↑ 3877.22%

	FY21	Y/Y Change
Operating Cash Flow	$13.6B	↑ 571.94%
Investing Cash Flow	$-8.5B	↑ 409.77%
Financing Cash Flow	$-873.0M	↓ 142.94%

	FY22	Y/Y Change
Operating Cash Flow	$5.0B	↓ 63.43%
Investing Cash Flow	$-5.2B	↓ 39.27%
Financing Cash Flow	$-3.4B	↑ 294.96%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-915.0M	↓ 25.31%
Investing Cash Flow	$1.9B	↓ 3.33%
Financing Cash Flow	$-668.0M	↑ 23.25%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-1.6B	↑ 74.86%
Investing Cash Flow	$789.0M	↓ 59.41%
Financing Cash Flow	$-58.0M	↓ 91.32%

Moderna Technicals Summary

Sell

Neutral

Buy

Moderna is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Moderna (MRNA) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Moderna, Inc.	-6.14%	-52.93%	-59.57%	-76.76%	93.42%
Biontech Se	7.35%	57.95%	33.59%	-31.3%	308.89%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.8%	8.05%	97.29%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	8.71%	82.07%	100.29%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	56.77%	86.78%	136.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Moderna, Inc.	24.73	NA	0.0	-9.22	-0.18	-0.1	NA	30.98
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Moderna, Inc.	Buy	$15.8B	93.42%	24.73	-43.77%
Biontech Se	Buy	$29.0B	308.89%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	97.29%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	100.29%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	136.62%	NA	-15.86%

About Moderna

Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel. The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells. The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the Moderna COVID-19 vaccine. The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more. The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion. The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies. The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'. Currently Moderna, Inc. has a market cap of $29.83 Billion. It has a P.E ratio of -5.08. The shares of Moderna, Inc. are trading at $39.42. .

Organization	Moderna
Employees	5600
CEO	Mr. Stephane Bancel
Industry	Health Technology

Management People of Moderna

Name	Title
Mr. Stephane Bancel	CEO & Director
Dr. Stephen Hoge M.D.	President
Mr. James M. Mock	Chief Financial Officer
Ms. Shannon Thyme Klinger J.D.	Chief Legal Officer & Corporate Secretary
Dr. Jerh Collins Ph.D.	Chief Technical Operations & Quality Officer
Ms. Lavina Talukdar CFA	Senior VP & Head of Investor Relations
Colleen Hussey	Senior Director of Corporate Communications
Ms. Tracey Franklin	Chief People & Digital Technology Officer
Dr. Melanie Ivarsson M.B.A., Ph.D.	Chief Development Officer
Mr. Dave Johnson	Chief Data & AI Officer

Important FAQs about investing in MRNA Stock from India :

What is Moderna share price today?

Moderna share price today stands at $39.42, Open: $41.19 ; Previous Close: $41.04 ; High: $41.41 ; Low: $39.37 ; 52 Week High: $170.47 ; 52 Week Low: $31.94.

The stock opens at $41.19, after a previous close of $41.04. The stock reached a daily high of $41.41 and a low of $39.37, with a 52-week high of $170.47 and a 52-week low of $31.94.

Can Indians buy Moderna shares?

Yes, Indians can invest in the Moderna (MRNA) from India.

With INDmoney, you can buy Moderna at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Moderna at zero transaction cost.

How can I buy Moderna shares from India?

It is very easy to buy Moderna from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Moderna (MRNA) be purchased?

Yes, you can buy fractional shares of Moderna with INDmoney app.

What are the documents required to start investing in Moderna stocks?

To start investing in Moderna, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.